

COVID-19 Information[Public health information \(CDC\)](#)[Research information \(NIH\)](#)[SARS-CoV-2 data \(NCBI\)](#)[Prevention and treatment information \(HHS\)](#)[Español](#)

> *Nat Prod Commun.* 2015 Jun;10(6):1009-12.

Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol

Ester Pagano, Vittorino Montanaro, Antonio Di Girolamo, Antonio Pistone, Vincenzo Altieri, Jordan K Zjawiony, Angelo A Izzo, Raffaele Capasso

PMID: 26197538

Abstract

There are anecdotal reports that some Cannabis preparations may be useful for bladder dysfunctions. Here, we investigated the effect of a number of non- psychotropic phytocannabinoids, namely cannabidiol (CBD), cannabigerol (CBG), cannabidivarin (CBDV), Δ^9 -tetrahydrocannabivarin (THCV) and cannabichromene (CBC) on mouse bladder contractility in vitro. CBG, THCV, CBD and CBDV, but not CBC, at concentration ranging from $10(-8)$ M to $10(-4)$ M, decreased (with similar potency), the contractions induced by acetylcholine without significantly modifying the contractions induced by electrical stimulation. The rank order of efficacy was $CBG=THCV>CBD>CBDV$. In depth studies on CBG showed that the effect of this phytocannabinoid on acetylcholine-induced contractions was not affected by CB1 or CB2 receptor antagonists. Additionally, CBG also reduced acetylcholine-induced contractions in the human bladder.

Related information

[MedGen](#)

[PubChem Compound \(MeSH Keyword\)](#)

LinkOut - more resources

Other Literature Sources

[The Lens - Patent Citations](#)

Research Materials

[NCI CPTC Antibody Characterization Program](#)

Miscellaneous

[NCI CPTAC Assay Portal](#)